New EUSA emerges from Jazz Pharma

EUSA Pharma, a newly-established profitable specialty pharmaceutical business with global reach, had its official launch following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals plc. The new company is led by Chief Executive Bryan Morton, who has over 30 years’ healthcare industry experience and previously founded two specialty pharmaceutical companies including the original EUSA Pharma business that was acquired by Jazz in 2012. The newly-established EUSA is supported by significant funding raised from leading healthcare growth equity investor Essex Woodlands, and the company has ambitious plans to accelerate its growth through acquisition and in-licensing. EUSA Pharma has commercial operations in the United States and key European markets, and a global distribution network serving approximately 40 other territories. The company has a portfolio of five approved and several named-patient specialty products, which had annual sales of approximately $27 million in 2014. EUSA is working closely with Jazz to provide a smooth transition of the products to ensure that patients will continue to receive their treatments.

• Caphosol is a supersaturated calcium phosphate rinse used as adjunct therapy, alongside standard care, in the treatment and prevention of oral mucositis, a common and debilitating side effect of radiation therapy and high-dose chemotherapy. The product is approved in the US, Europe and a number of other territories, including Australia and Hong Kong.
• Collatamp is a lyophilized collagen surgical implant impregnated with the antibiotic gentamicin and is used in hemostasis in surgeries with high risk of infection. It is approved in Europe, South America, the Middle East and South-East Asia, and a number of other countries including Canada, Australia and New Zealand. EUSA Pharma has global rights to the product outside the USA.
• Custodiol is a pre-prepared solution with a regulatory approval in France for use in the hypothermic storage and preservation of organs for transplantation (heart, kidney, liver and pancreas).
• Fomepizole is a pharmacological antidote approved in a number of European countries for the treatment of poisoning with ethylene glycol, a compound commonly used in antifreeze.
• Xenazine is approved for the treatment of movement disorders associated with Huntington's chorea and hemiballismus, and EUSA Pharma has commercial rights to the product in France.